Skip to main content
. Author manuscript; available in PMC: 2015 Dec 17.
Published in final edited form as: Lancet. 2014 Feb 17;383(9930):1762–1770. doi: 10.1016/S0140-6736(13)61682-7

Table 4.

Hib vaccine-preventable disease incidence for pneumonia and meningitis in Indonesia6

Control incidence* VE (%) VPDI*†
Pneumonia outcomes
Clinical pneumonia 395   4.0%‡ 15.8
Hospital admission or clinical assessment of severe pneumonia   54.6   4.8%   2.6
Hospital admission for severe pneumonia   45.2   3.8%   1.7
Radiological consolidation or pleural effusion with WHO criteria18     8.9 −4.9% −0.43
Meningitis outcomes
Hospital admission for meningitis or clinic assessment for seizures     7.0 22%‡   1.6
Hospital admission for meningitis     5.4 16%   0.87
Probable bacterial or confirmed Hib     0.86 55%‡   0.47
Microbiologically confirmed Hib     0.19 86%‡   0.16

Hib=Haemophilus influenzae type b. VE=Vaccine effectiveness. VPDI=vaccine-preventable disease incidence.

*

All incidences are per 1000 person-years of follow-up.

†

VPDI is calculated as the vaccine effectiveness multiplied by the control group incidence, and is shown per 1000 person-years of follow-up in children from age of first vaccination to age 2 years.

‡

VE has 95% CIs that exclude 0.